Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma

Zevalin Plus Nonmyeloablative Allogeneic Transplantation Effective in High-Risk B-Cell NHL (03-29-2013)

The addition of Zevalin® (ibritumomab tiuxetan) to nonmyeloablative allogeneic transplantation (NMAT) is safe and produces early responses and prolonged disease control in high-risk patients with B-cell non-Hodgkin’s lymphoma, according to the results... Continue Reading

Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma (03-22-2013)

Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of... Continue Reading

Dose-Dense R-CHOP plus Zevalin Improves Response in Diffuse Large B-Cell Lymphoma (03-1-2013)

Dose-dense R-CHOP followed by Zevalin® (ibritumomab tiuxetan) converts partial responses to complete responses and maintains durable responses in patients with untreated diffuse large B-cell lymphoma, according to the results of a study presented at... Continue Reading

Sequential R-CHOP plus Zevalin Shows Promise in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (02-22-2013)

Sequential R-CHOP followed by Zevalin® (ibritumomab tiuxetan) produces encouraging outcomes in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society... Continue Reading

Zevalin Safe and Effective in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (02-15-2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and effective in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study published in Clinical Cancer Research Non-Hodgkin’s lymphoma... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (03-14-2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

Adcetris Approved for Two Types of Lymphoma (08-26-2011)

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin... Continue Reading

Conventional Chemoimmunotherapy Superior to Intensive Therapy with Autologus Stem Cell Support for Aggressive B-Cell Lymphoma (06-20-2011)

Researchers affiliated with the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) have reported that conventional chemoimmunotherapy was superior to sequential high-dose chemotherapy with autologous stem cell support for the treatment of high-risk... Continue Reading

Brentuximab Vedotin Effective for Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma (06-16-2011)

Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed or refractory anaplastic large cell lymphoma. The details of this study were reported at the 2011 meeting... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (05-23-2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

« Previous PageNext Page »